Stablepharma, with its commercial and academic partners, has generated strong in-vitro and in-vivo data for its vaccine programmes including Tetadif (Td) and COVID mRNA. Studies have shown repeatedly that StablevaX™ elicits a strong immune response in animals even after being exposed to high temperatures for long periods of time.

Stablepharma has a strategic R&D and commercialisation partnership agreement in place with the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio) with the aim to produce the world’s first ‘fridge free’ Td-StablevaX™ vaccine.

We have established partnerships with two leading UK Universities: University of Southampton to conduct our First in Human Clinical Trials for the Td vaccine; and the University of Strathclyde to progress our mRNA stabilisation project for Covid-19 vaccines.

Stablepharma has worked with the UK’s The National Institute for Biological Standards and Control (NIBSC) to conduct animal trials, in order to confirm that the StablevaX™ tetanus vaccine induces the same level of antibody response as the positive control vaccine.

Innovate UK has provided grant funding to Stablepharma to progress the R&D and product development work for the StablevaX™ Td vaccine.